Key Highlights

● Park Ha Biological Technology fell roughly 11.3% in the latest session, consistent with the stock's history of large daily swings.

● Shares outstanding total only about 757,000, for a market Capitalization of roughly $2.4 million, with a 52-week range of approximately $2.56 to $316.00.

● The company IPO'd on Nasdaq in late December 2024 at $4.00 per share, before an approximately 93% single-session collapse on July 8, 2025 that a securities lawsuit says marked the unraveling of an alleged scheme.

● A $2.0 million registered direct offering completed in June 2026 adds to dilution concerns, with a lead-plaintiff deadline of September 28, 2026 in the pending litigation.

Shares of Park Ha Biological Technology (NASDAQ: BYAH), a Chinese skincare company formerly trading under the ticker PHH, fell about 11.3% in a recent session as a wave of securities class-action reminders drew fresh attention to the company's thinly floated 2024 initial public offering. Multiple law firms have publicized a federal lawsuit alleging that Park Ha's IPO was deliberately structured with an extremely low public float to enable a stock-manipulation scheme that collapsed in 2025. With a micro-cap valuation of only a few million dollars and a razor-thin share count, BYAH remains extraordinarily volatile, and the renewed litigation spotlight is the backdrop for its latest slide.

What Happened?

In early-to-mid August 2026, a series of law firms, including the Rosen Law Firm, Robbins LLP and Morris Kandinov LLP, among others, issued investor notices reminding shareholders of a securities class action pending against Park Ha Biological Technology and of a September 28, 2026 deadline to seek lead-plaintiff status. The suit, captioned Robert Thomas, et al. v. Park Ha Biological Technology Co., Ltd. (No. 26-cv-6421), was filed in the U.S. District Court for the Southern District of New York.

The complaint covers a class period of December 27, 2024, the date of the company's IPO, through July 8, 2025. It alleges that Park Ha was the subject of a fraudulent stock-promotion scheme involving social-media misinformation and impersonators posing as financial professionals, and that the offering was "intentionally structured with an extremely low public float" to facilitate the alleged manipulation. According to the filing, the scheme collapsed on July 8, 2025, when the shares fell roughly 93% in a single trading session. The recent decline in BYAH stock came as these litigation reminders circulated.

Why Is BYAH Stock Falling?

The most plausible driver of the recent weakness is the renewed publicity around the securities litigation, which has kept the company's governance and IPO structure in the spotlight ahead of the September lead-plaintiff deadline. That said, causation should be stated carefully: BYAH is an exceptionally thin, low-float micro-cap whose shares routinely swing by double digits in a single session, so attributing any one day's move solely to the lawsuit reminders would overstate the evidence. The move followed the litigation notices, but the stock's structural Volatility is itself a major factor.

The confirmed facts are that multiple firms are actively soliciting plaintiffs, that the underlying complaint alleges an orchestrated pump-and-dump enabled by a minimal float, and that the stock already suffered a catastrophic single-session collapse in July 2025. For prospective investors, the combination of ongoing litigation, a tiny tradable share base and a history of extreme price swings creates persistent overhang and elevated risk, conditions under which sharp declines are common and often unaccompanied by any fresh company-specific news.

The Numbers Investors Are Watching

- Recent move: a decline of roughly 11.3% in the latest session, consistent with the stock's history of large daily swings.

- Float and size: shares outstanding of only about 757,000, with a market capitalization of roughly $2.4 million, a genuine micro-cap.

- 52-week range: approximately $2.56 to $316.00, illustrating the extraordinary volatility since the IPO.

- IPO: priced December 27, 2024 at $4.00 per share, offering 1,200,000 ordinary shares and raising about $4.8 million.

- The July 8, 2025 collapse: an approximately 93% single-session drop that the lawsuit says marked the scheme's unraveling.

- Recent financing: a $2.0 million registered direct offering completed in June 2026.

- Trailing financials: Revenue of about $2.5 million and a net loss of roughly $5.5 million.

- Litigation deadline: September 28, 2026 to move for lead-plaintiff status.

The Bigger Picture

Park Ha Biological Technology is a China-based skincare and cosmetics company that sells products through retail stores and franchisees. It went public on Nasdaq in late December 2024 in a small offering, and, like a number of low-float small-cap listings of Chinese companies in recent years, its shares experienced a violent boom-and-bust. The class action names not only company officers and directors but also its auditor, WWC P.C., and IPO underwriters Dawson James Securities and D. Boral Capital LLC, and asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 as well as Sections 11, 12(a)(2) and 15 of the Securities Act of 1933.

More recently, the company has tried to shift the narrative toward growth, announcing a cooperation with Amazon in North America, an application for membership in the Personal Care Products Council, and partnerships aimed at building an artificial-intelligence-driven beauty ecosystem. Whether those initiatives can offset the reputational and legal overhang from the manipulation allegations remains to be seen, particularly given the company's small revenue base and continuing losses.

What Could Happen Next?

The clearest near-term catalyst is the September 28, 2026 lead-plaintiff deadline, after which the litigation will move toward the appointment of lead counsel and, eventually, motions and potential settlement or dismissal proceedings, a process that can take years. Investors should also watch for any additional financings; with only a few million dollars of Market Value and ongoing losses, further capital raises are plausible and could be dilutive given the tiny share count. Company announcements on the Amazon relationship, product expansion and the AI-beauty partnerships could spark sharp moves in either direction because of the thin float. Any Nasdaq listing or compliance developments would also be significant. Given the stock's volatility, outsized swings are likely to continue regardless of fresh fundamental news.

Bottom Line

BYAH's roughly 11.3% decline came as law firms intensified publicity around a securities class action that centers on the very feature that makes the stock so volatile: an IPO alleged to have been structured with an extremely low public float to enable manipulation. The lawsuit, the July 2025 collapse and the sub-$3-million market value all point to a speculative, high-risk situation where large daily moves are the norm rather than the exception. The most important things to monitor are the September 28 lead-plaintiff deadline, any new financings or dilution, and whether the company's growth announcements gain real traction. Until the litigation overhang clears, BYAH is likely to remain extremely risky and prone to violent swings.